C1QTNF2

C1QTNF2 (CTRP2) is a secreted adipose- and muscle-associated glycoprotein that functions as a metabolic regulator of lipid handling, glucose uptake, and vascular responses (PMID:18783346, PMID:31439668). It assembles into trimers as its basic structural unit and can heterotrimerize with CTRP7 and adiponectin, generating a repertoire of functionally distinct circulating ligands (PMID:18783346). In adipose tissue CTRP2 acts as a suppressor of lipolysis: its loss in knockout mice upregulates lipolytic enzyme expression and protein kinase A signaling, while recombinant CTRP2 suppresses triglyceride hydrolysis in cultured adipocytes (PMID:31439668). CTRP2 also shapes hepatic lipid metabolism, with deficiency producing elevated hepatic triglyceride secretion, reduced hepatic triglyceride and cholesterol content, and lipidomic shifts in diacylglycerols and phospholipids consistent with altered membrane remodeling (PMID:31439668). Consistent with these in vitro and loss-of-function findings, gain-of-function transgenic mice show improved insulin tolerance and enhanced capacity to handle a lipid challenge on a high-fat diet (PMID:24586339). In cardiomyocytes CTRP2 drives GLUT1/GLUT4 translocation and glucose uptake through AMPK activation positioned upstream of Akt, partly via adiponectin receptor 1 (PMID:33919975), and recombinant CTRP2 promotes endothelial angiogenesis through AKT–VEGFR2 signaling while limiting infarct size in ischemia/reperfusion models (PMID:36409464). The C1q globular domain is sufficient for biological activity (PMID:21453774). No structural model of its receptor engagement or a unifying account linking its distinct tissue activities has been characterized in the available corpus.

1. 2008 Medium

   Established that CTRP2 is a secreted glycoprotein with defined oligomeric architecture and intrinsic metabolic activity, distinguishing it from a passive serum component.

   Evidence Mammalian cell expression with size-exclusion chromatography and co-secretion; in vitro myotube assays of glycogen and fat oxidation

   PMID:18783346

   Open questions at the time

   • Receptor mediating myotube effects not identified
   • Physiological relevance of heterotrimers with CTRP7/adiponectin untested in vivo
   • No structural model of the trimer-receptor interface
2. 2014 Medium

   Tested whether circulating CTRP2 affects whole-body metabolism, showing gain-of-function improves insulin tolerance and lipid handling.

   Evidence CTRP2-overexpressing transgenic mice with insulin tolerance test and acute lipid challenge on high-fat diet

   PMID:24586339

   Open questions at the time

   • Tissue source of the metabolic benefit not resolved
   • Signaling pathway not defined in this model
   • Overexpression may not reflect endogenous dose
3. 2019 High

   Defined the endogenous role and a molecular pathway, placing CTRP2 as a suppressor of PKA-mediated adipose lipolysis and a regulator of hepatic triglyceride secretion.

   Evidence Knockout mice with lipid/metabolomic profiling and oral gavage, plus rescue by recombinant CTRP2 in cultured adipocytes and PKA signaling assays

   PMID:31439668

   Open questions at the time

   • Receptor coupling CTRP2 to PKA suppression unidentified
   • Mechanism linking membrane lipid remodeling to hepatic TG secretion not established
   • Direct vs. indirect action on hepatocytes unresolved
4. 2021 Medium

   Identified an intracellular signaling order in cardiomyocytes, placing AMPK upstream of Akt in CTRP2-driven glucose uptake and implicating AdipoR1.

   Evidence Recombinant CTRP2 on primary cardiomyocytes and H9C2 cells with GLUT translocation/uptake assays, pharmacological AMPK/Akt inhibition, and AdipoR1 knockdown

   PMID:33919975

   Open questions at the time

   • AdipoR1 loss abolished only some effects, leaving the full receptor set unknown
   • Pharmacological inhibitor specificity limits pathway ordering
   • In vivo cardiac glucose handling not tested
5. 2022 Medium

   Extended CTRP2 function to the vasculature, showing it promotes angiogenesis via AKT-VEGFR2 and confers cardioprotection in ischemia.

   Evidence Endothelial tube formation/migration assays with Western blot for AKT/VEGFR2, plus recombinant CTRP2 injection in mouse I/R and hindlimb ischemia models

   PMID:36409464

   Open questions at the time

   • Direct receptor on endothelial cells not defined
   • Whether VEGFR2 induction is transcriptional or post-translational unresolved
   • Cardioprotection mechanism vs. angiogenesis not separated

• How CTRP2 engages its receptor(s) at the structural level and how its distinct tissue-specific activities (adipose lipolysis suppression, hepatic TG secretion, cardiac glucose uptake, endothelial angiogenesis) are unified by a common mechanism remains unresolved.
• No definitive cognate receptor mapped across all tissues
• No structural model of ligand-receptor engagement
• Relationship between AMPK/Akt and PKA pathways across tissues unintegrated